期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白细胞介素-36与SYNTAX评分的相关性 被引量：1

下载PDF
导出
摘要 目的探讨白细胞介素(IL)-36三种亚型与SYNTAX评分的相关性,为进一步认识冠状动脉粥样硬化的炎症机制提供依据。方法选取接受冠脉动脉造影术或经皮冠状动脉介入术诊疗的冠心病患者349例,依据造影结果计算SYNTAX评分风险分级,分为低风险组237例、中等风险组71例及高风险组41例,采用酶联免疫吸附法检测血清IL-36α、IL-36β及IL-36γ的浓度,与SYNTAX评分风险分级进行相关性分析。结果 IL-36α与SYNTAX评分风险分级无明显相关性(P=0.273),IL-36β及IL-36γ与SYNTAX评分风险分级明显相关(P<0.05)。结论 IL-36β及IL-36γ很有可能参与冠状动脉粥样硬化的发生、发展,在冠心病的炎症过程中发挥重要作用。
作者 徐基瑛 赵一俏 崔同涛 靳文 谢治球 陈森
机构地区 南方医科大学非直属附属广东省第二人民医院 广东省心血管病研究所心内科 南华大学医学院
出处 《广东医学》 CAS 北大核心 2016年第21期3242-3244,共3页 Guangdong Medical Journal
关键词 冠心病 IL-36 SYNTAX 炎症
分类号 R392.12 [医药卫生—免疫学]
  • 相关文献

参考文献2

二级参考文献46

  • 1Ryan TJ, Faxon DE Gunnar RM, Kennedy JW, King SB, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American college of cardiology/American heart association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Circulation 1988; 78: 486-502.
  • 2Ellis SG, Vandormael MG, Cowley MJ, Whitlow PL, Schneider JP, Topol EJ. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 1990; 82:1193-1202.
  • 3Hamburger JN, Serruys PW, Scabra-Gomes R, Simon R, Koolen J J, Fleck E, et al. Recanalization of total coronary occlusions using a laser guidewire (the European TOTAL Surveillance Study). Am J Cardiol 1997; 80: 1419-1423.
  • 4Iwakura K, Ito H, Ikushima M, Okamura A, Asano K, Kuroda T, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41: 1-7.
  • 5Lefevre T, Louvard Y, Morice MC, Dumas P, Loubeyre C, Benslimane A, et al. Stenting of bifurcation lesions: classification, treatments, and results. Catheter Cardiovasc Interv 2000; 49: 274-283.
  • 6Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
  • 7Gyongyosi M, Christ G, Lang I, Kreiner G, Sochor H, Probst E et al. Two-year results of the AUTAX (Austrian Multivessel TAXUS-Stent) registry beyond the SYNTAX (synergy.between percutaneous coronary intervention with TAXUS and cardiac surgery) study. JACC Cardiovasc Interv 2009; 2: 718-727.
  • 8Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern M J, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.
  • 9Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
  • 10Kirtane A J, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-elating and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.

共引文献55

同被引文献12

引证文献1

二级引证文献2

广东医学
2016年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部